Clinical trials
Observational Hepatoblastoma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
16 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2011 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Recruiting | 3 |
| Unknown status | 3 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Children's Oncology Group | 3 |
| Assiut University | 1 |
| Children's Hospital Medical Center, Cincinnati | 1 |
| Federation Francophone de Cancerologie Digestive | 1 |
| Nemours Children's Clinic | 1 |
| Paul G. Kemps, MD | 1 |
| RenJi Hospital | 1 |
| Shanghai Children's Medical Center | 1 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
| University Hospital, Strasbourg, France | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hepatoblastoma | 16 |
| Neuroblastoma | 5 |
| Carcinoma, Hepatocellular | 4 |
| Liver Neoplasms | 3 |
| Medulloblastoma | 3 |
| Neoplasms | 3 |
| Sarcoma | 3 |
| Wilms Tumor | 3 |
| Burkitt Lymphoma | 2 |
| Central Nervous System Neoplasms | 2 |
Trials
Showing 76 to 16 of 16. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.